Overview

• The experimental peptide is engineered to act on GLP-1, GIP, glucagon and PYY to influence appetite, blood sugar and energy use.
• Researchers describe a goal of long-lasting weight loss of about 30%, approaching outcomes typically associated with bariatric surgery.
• Evidence so far comes from cell assays, with no animal studies or human clinical trials reported.
• The design seeks to distribute effects across pathways to limit nausea and metabolic tradeoffs, emphasizing GIP’s anti-nausea signaling alongside GLP-1, PYY and glucagon.
• Findings were published in the Journal of the American Chemical Society, and outside experts urged cautious in‑vivo testing, noting glucagon may raise heart rate and affect the liver.